Merck

@Merck • 216,815 subscribers

We aspire to be the premier research-intensive biopharmaceutical company. Intended for U.S. residents only. FLS: https://t.co/QUXfCXVlx3

Shorts

13,912 views

12,055 views

24,648 views

Videos

sweetdream.ai

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Private Show

Join now for exclusive access

Free preview available • Premium content

131,252,154 views • 2 months ago

41,090,155 views • 2 months ago

10,414,963 views • 2 months ago

6,214,797 views • 2 months ago

7,585,683 views • 2 months ago

7,361,711 views • 2 months ago

40,420,107 views • 1 year ago

15,869,000 views • 6 months ago

29,382,947 views • 1 year ago

18,788,109 views • 1 year ago

3,016,540 views • 9 months ago

2,198,326 views • 9 months ago

13,655 views • 27 days ago

15,686 views • 1 month ago

44,240 views • 8 months ago

16,948 views • 2 months ago

10,323 views • 1 month ago

10,157 views • 2 months ago

No more content to load

Live Cam

Merck

Shorts

Every day, our scientists tackle challenging problems like the scalable synthesis of complex molecules. In this latest publication in Science Magazine, we share how we’re using #biocatalysis to manufacture orally available macrocyclic peptides. Learn more:

Join us today at 9 a.m. ET to learn more about our Q1 2026 #earnings: $MRK

Today, we announced positive topline results from two of our Phase 3 clinical studies in #pneumococcal disease. Read more about our latest news:

Videos

Watch Anya Live

We believe great medicines start with great conversations.

With our broad set of global resources, we work alongside our partners to move bold science forward.

Our One Pipeline strategy enables us to advance bold science, whether it comes from our own labs or from our collaborator’s labs.

Our business development and licensing team looks for opportunities to complement and augment our pipeline where science and value align.

We believe great medicines start with great conversations.

With our broad set of global resources, we work alongside our partners to move bold science forward.

People with cancer deserve more – that’s what drives every new pathway and technology we investigate and every partnership we pursue. Our research focuses on exploring novel approaches to help patients fight cancer.

We believe great medicines start with great conversations.

Helping to address barriers to cancer screenings and care, reducing disparities and expanding access are just some of the ways we work every day to shape the outcomes for people with cancer.

Situated in the heart of San Diego's high-tech innovation hub, our state-of-the-art labs foster innovation and seamless collaboration among our scientists. Take a look inside:

Our scientists are advancing the largest pipeline in our company’s history. And the numbers speak for themselves — take a look at our science in action.

It can take up to 10 years for a single molecule to become a medicine. But where does the process even begin? From discovery to distribution, follow the steps in the journey of a molecule to find out.

Today at #ASCO26, in collaboration with Moderna, we're proud to present five-year follow-up results from a Phase 2b study evaluating our investigational individualized neoantigen therapy for #melanoma. Learn more:

We’re presenting new data at #ASCO26 from our robust oncology portfolio and pipeline across earlier-stage and advanced tumor types. We’re focused on advancing research to fight cancer and evaluate new approaches to help prolong and protect lives. Learn more:

Today we broke ground on a $3B, 400,000-sq. foot pharmaceutical manufacturing facility at our Elkton, Virginia site. Real projects. Not just promises.

Today we announced the initiation of a pivotal Phase 2b/3 trial for the treatment of patients with neovascular age-related macular degeneration (#wetAMD). Learn more: #ophthalmology

Today, Merck completed the acquisition of Terns Pharmaceuticals, further strengthening our #oncology portfolio and reinforcing our focus on science‑driven innovation. Learn more: